Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
21 February 2024 - 12:00AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced that it will host a virtual Key Opinion
Leader (KOL) event featuring Stephen Harrison, MD, Visiting
Professor in the Radcliffe Department of Medicine at the University
of Oxford, UK, to discuss the unmet need and current treatment
landscape for patients with metabolic dysfunction-associated
steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase
2a HERALD study, intended to evaluate the safety and efficacy of
ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET. To register,
click here.
During the event, Dr. Harrison will also discuss some of the key
differentiating features of ALG-055009, a next generation thyroid
hormone beta agonist. A live question and answer will follow the
formal presentation.
About Stephen Harrison, MD
Stephen Harrison, MD, is the Founder and Chairman of Pinnacle
Clinical Research and Co-Founder and Chairman of Summit Clinical
Research, LLC in San Antonio, Texas. Dr. Harrison earned his
medical degree from the University of Mississippi School of
Medicine. He completed his internal medicine residency and
gastroenterology fellowship at Brooke Army Medical Center before
completing a 4-year advanced liver disease fellowship at Saint
Louis University. Dr. Harrison served as a Professor of Medicine at
the Uniformed Services University of the Health Sciences and is
currently a Visiting Professor of Hepatology at Radcliffe
Department of Medicine, University of Oxford.
Dr. Harrison also served as a Colonel in the United States Army.
Retiring in 2016, he concluded more than 20 years of dedicated
service to his country. During his army tenure, he served as the
Director of Graduate Medical Education at Brooke Army Medical
Center, Associate Dean for the San Antonio Uniformed Services
Health Education Consortium and Gastroenterology Consultant to the
Army Surgeon General. He is a past Associate Editor for Hepatology
and Alimentary Pharmacology and Therapeutics. He is internationally
known for his work in non-alcoholic fatty liver disease (NAFLD)
with over 350 peer-reviewed publications in top-tier journals
including the New England Journal of Medicine, Nature Medicine,
Lancet, Lancet Gastroenterology and Hepatology, Gastroenterology,
Journal of Hepatology and Hepatology. He has an H-Index of 106 with
more than 50,000 citations.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical
company that was founded in 2018 with the mission to become a world
leader in the treatment of liver and viral diseases. Aligos’
strategy is to harness the deep expertise and decades of drug
development experience its team has in liver and viral diseases to
discover and develop potentially best in class therapeutics for
metabolic dysfunction-associated steatohepatitis (MASH, previously
known as NASH) and viruses with high unmet medical need such as
coronaviruses and chronic hepatitis B (CHB).
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered “forward-looking statements.”
Forward-looking statements are typically, but not always,
identified by the use of words such as “may,” “will,” “would,”
“believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,”
and other similar terminology indicating future results. Such
forward looking statements are subject to substantial risks and
uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, the risks and
uncertainties inherent in the drug development process, including
Aligos’ clinical stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, the
timing of regulatory filings, and the challenges associated with
manufacturing drug products. For a further description of the risks
and uncertainties that could cause actual results to differ from
those anticipated in these forward-looking statements, as well as
risks relating to the business of Aligos in general, see Aligos’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 02, 2023 and its future periodic
reports to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
CompanyJordyn TaraziVice
President, Investor Relations & Corporate Communications(650)
910-0427jtarazi@aligos.com
Media ContactVeronica
EamesLifeSci Communicationsveames@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2023 to Apr 2024